Figure 5

Cerebrospinal fluid levels of Aβ42, t-tau and p-tau, but not amyloid-beta oligomers, distinguish Alzheimer’s disease subjects from age-matched controls in Cohort 1. Cerebrospinal fluid (CSF) from 10 Alzheimer’s disease (AD) and 10 aged control (CON) subjects were analyzed for amyloid-beta oligomers (oAβ) (A), Aβ42 (B), total tau (C) and phosphorylated tau (D). Aβ42 quantified with monoclonal antibodies (mAbs) 21 F12 for capture and 3D6 for detection (unpaired, two-tailed t test with Welch’s correction, P <0.0001). Total tau quantified with mAbs AT120 for capture and HT7 + BT2 for detection (unpaired, two-tailed t test with Welch’s correction, P <0.0001). Tau phosphorylated at Thr181 quantified with of HT7 for capture and AT120 for detection (unpaired, two-tailed t test with Welch’s correction, P <0.0001). Horizontal bars, medians and interquartile ranges. Dashed line crosses y axis at 0.15 pg/ml, indicating the lower limit of reliable quantification. Erenna platform (Singulex, Alameda, CA, USA).